共 89 条
[1]
Jubb AM(2010)Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol 11 1172-1183
[2]
Harris AL(2009)Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression Hypertension 54 652-658
[3]
Facemire CS(2009)Arterial hypertension correlates with clinical outcome in cokorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 227-230
[4]
Nixon AB(2010)Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 596-604
[5]
Grifiths R(2008)Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 4672-4678
[6]
Hurwitz H(2010)Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2137-2143
[7]
Coffman TM(2010)Clinical course of advanced non-small-cel lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 949-954
[8]
Scartozzi M(2010)Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib J Exp Clin Cancer Res 29 95-1213
[9]
Galizia E(2011)Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients Cancer Chemother Pharmacol 68 1207-1535
[10]
Chiorrini S(2003)A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated PBM cells Hum Immunol 64 S125-448